Cargando…

Pathological complete response of HER2-positive breast cancer to trastuzumab and chemotherapy can be predicted by HSD17B4 methylation

Human epidermal growth factor (HER) 2-directed therapy is the standard treatment for HER2-positive breast cancer. Patients who achieved a pathological complete response (pCR) to the therapy are associated with excellent disease-free survival. However, few molecular markers are available to predict p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fujii, Satoshi, Yamashita, Satoshi, Yamaguchi, Takeshi, Takahashi, Masato, Hozumi, Yasuo, Ushijima, Toshikazu, Mukai, Hirofumi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5386667/ https://www.ncbi.nlm.nih.gov/pubmed/28186977 http://dx.doi.org/10.18632/oncotarget.15118

Ejemplares similares

Multi-omics analyses identify HSD17B4 methylation-silencing as a predictive and response marker of HER2-positive breast cancer to HER2-directed therapy
por: Yamashita, Satoshi, et al.
Publicado: (2020)

Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 study
por: Mukai, Hirofumi, et al.
Publicado: (2020)

Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer
por: Shitara, Kohei, et al.
Publicado: (2021)

Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab
por: Cheng, Huan, et al.
Publicado: (2014)

Cost-Effectiveness of Trastuzumab With or Without Chemotherapy as Adjuvant Therapy in HER2-Positive Elderly Breast Cancer Patients: A Randomized, Open-Label Clinical Trial, the RESPECT Trial
por: Takumoto, Yuki, et al.
Publicado: (2022)

Survival Outcomes of Retreatment with Trastuzumab and Cytotoxic Chemotherapy for HER2-Positive Recurrent Patients With Breast Cancer Who Had Been Treated with Neo/adjuvant Trastuzumab Plus Multidrug Chemotherapy: A Japanese Multicenter Observational Study
por: Yamashiro, Hiroyasu, et al.
Publicado: (2018)

Adjuvant trastuzumab without chemotherapy for treating early HER2-positive breast cancer in older patients: A propensity score-adjusted analysis of a prospective cohort study
por: Sawaki, Masataka, et al.
Publicado: (2022)

Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer
por: Palmieri, Carlo, et al.
Publicado: (2015)

Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
por: Natoli, Clara, et al.
Publicado: (2013)

Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors
por: Buzatto, I.P.C., et al.
Publicado: (2017)

Analyses of Molecular Characteristics and Enzymatic Activities of Ovine HSD17B3
por: Islam, Mohammad Sayful, et al.
Publicado: (2021)

Mixed adenoneuroendocrine carcinoma with loss of HER2 positivity after trastuzumab-based chemotherapy for HER2-positive gastric cancer: a case report
por: Nagata, Hiromi, et al.
Publicado: (2020)

Degree of methylation burden is determined by the exposure period to carcinogenic factors
por: Takeshima, Hideyuki, et al.
Publicado: (2017)

THU574 Hsd17b1 Partially Compensates For The Lack Of Hsd17b3 In Testicular Testosterone Production In Fetal Mice, But Not In Adults
por: Poutanen, Matti, et al.
Publicado: (2023)

Pathologic Complete Response Achieved in Early-Stage HER2-Positive Breast Cancer After Neoadjuvant Therapy With Trastuzumab and Chemotherapy vs. Trastuzumab, Chemotherapy, and Pertuzumab: A Systematic Review and Meta-Analysis of Clinical Trials
por: Fazal, Faizan, et al.
Publicado: (2023)

ALK-Rearranged NSCLC With Concomitant HER2-Mutant Breast Cancer Patient Treated With Alectinib, Trastuzumab, and Pertuzumab: A Case Report
por: Takayasu, Hirokazu, et al.
Publicado: (2023)

The Effectiveness of Trastuzumab Combined with Sequential Chemotherapy for Metastatic Gastric Carcinoma with Overexpression of HER2
por: Saavedra Santa Gadea, Omar, et al.
Publicado: (2017)

Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer
por: Dackus, Gwen M. H. E., et al.
Publicado: (2020)

Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
por: Cheong, E. Von, et al.
Publicado: (2021)

Impact of dose-dense neoadjuvant chemotherapy on pathologic response and survival for HER2-positive breast cancer patients who receive trastuzumab
por: Wang, Lize, et al.
Publicado: (2021)

Combination of Near-Infrared Photoimmunotherapy Using Trastuzumab and Small Protein Mimetic for HER2-Positive Breast Cancer
por: Yamaguchi, Haruka, et al.
Publicado: (2021)

Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer
por: Kurozumi, Sasagu, et al.
Publicado: (2019)

Safety and efficacy of HER2 blockade by trastuzumab-based chemotherapy-containing combination strategies in HER2+ gastroesophageal adenocarcinoma
por: Catenacci, D.V.T., et al.
Publicado: (2021)

Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study
por: Ueno, Takayuki, et al.
Publicado: (2019)

Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer
por: Wakatsuki, Takeru, et al.
Publicado: (2018)

Biallelic mutation of HSD17B4 induces middle age–onset spinocerebellar ataxia
por: Matsuda, Yukiko, et al.
Publicado: (2020)

Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study
por: Sawaki, Akira, et al.
Publicado: (2011)

Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes
por: Ishida, Takanori, et al.
Publicado: (2008)

HER2/CEP17 Ratios and Clinical Outcome in HER2-Positive Early Breast Cancer Undergoing Trastuzumab-Containing Therapy
por: Stocker, Albina, et al.
Publicado: (2016)

Long-term combination chemotherapy using eribulin and trastuzumab for three patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
por: Saeki, Toshiaki, et al.
Publicado: (2016)

HSD17B13: A Potential Therapeutic Target for NAFLD
por: Zhang, Hai-bo, et al.
Publicado: (2022)

Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06)
por: Kimura, Yutaka, et al.
Publicado: (2017)

Effect of Trastuzumab Deruxtecan on QT/QTc Interval and Pharmacokinetics in HER2‐Positive or HER2‐Low Metastatic/Unresectable Breast Cancer
por: Shimomura, Akihiko, et al.
Publicado: (2022)

Development of a Novel Output Value for Quantitative Assessment in Methylated DNA Immunoprecipitation-CpG Island Microarray Analysis
por: Yamashita, Satoshi, et al.
Publicado: (2009)

Comparison of Placental HSD17B1 Expression and Its Regulation in Various Mammalian Species
por: Yazawa, Takashi, et al.
Publicado: (2023)

Effect of Trastuzumab–HER2 Complex Formation on Stress-Induced Modifications in the CDRs of Trastuzumab
por: Spanov, Baubek, et al.
Publicado: (2022)

Pathological Complete Response with Neoadjuvant Trastuzumab Combined with Chemotherapy in HER2 Positive Breast Cancer: A Single Institution Retrospective Analysis from Vietnam
por: Phung, Huyen Thi, et al.
Publicado: (2020)

PIK3CA mutations are associated with pathologic complete response rate to neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer
por: Shi, Qiyun, et al.
Publicado: (2022)

Survival of patients with metastatic HER2 positive gastro-oesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on front-line chemotherapy plus trastuzumab
por: Nevala-Plagemann, Christopher, et al.
Publicado: (2019)

Estimation of the Fraction of Cancer Cells in a Tumor DNA Sample Using DNA Methylation
por: Takahashi, Takamasa, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_i3n8adlduu2mo93d5n6pbn79dv